Angiotensin II upregulates the expression of profibrotic cytokines leading to pulmonary fibrosis and severe inflammation with increased vascular permeability, a scenario that may be attenuated by angiotensinogen converting enzyme (ACE) inhibitors and angiotensin receptor blocker (ARB) therapies [40]. This evidence concerns the gene AGT and pulmonary fibrosis.